1. Home
  2. TNET vs OCS Comparison

TNET vs OCS Comparison

Compare TNET & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$47.58

Market Cap

1.7B

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

HOLD

Current Price

$11.20

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
OCS
Founded
1988
2003
Country
United States
Switzerland
Employees
2700
60
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
TNET
OCS
Price
$47.58
$11.20
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$65.80
$42.00
AVG Volume (30 Days)
360.2K
1.1M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
N/A
EPS
1.90
N/A
Revenue
$5,010,000,000.00
N/A
Revenue This Year
N/A
$466.06
Revenue Next Year
$3.30
$479.73
P/E Ratio
$25.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.67
$10.52
52 Week High
$77.61
$34.48

Technical Indicators

Market Signals
Indicator
TNET
OCS
Relative Strength Index (RSI) 63.42 22.63
Support Level $34.47 N/A
Resistance Level $49.50 $21.82
Average True Range (ATR) 1.94 1.80
MACD 0.13 -0.99
Stochastic Oscillator 78.87 3.27

Price Performance

Historical Comparison
TNET
OCS

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Share on Social Networks: